HealthcareFirms.com » Anti-infectives

Pharmasset, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV).

Vertex Pharmaceuticals

admin — Tue, 02 Mar 2010 18:40:16 +0000

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

NovaBay Pharmaceuticals, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

NovaBay Pharmaceuticals is a clinical stage company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections. The company’s Aganocide compounds mimic the body’s immune system, acting rapidly and effectively to defeat multi-drug resistant pathogens without causing resistance. NovaBay’s lead Aganocide compound is in Phase 2 clinical testing for treating Pink Eye, Impetigo and Catheter-Associated Urinary Tract Infection. The company has significant corporate partnerships with Alcon, the world’s leading ophthalmology company, and Galderma S.A., a global pharmaceutical firm dedicated to dermatology. NovaBay has also retained proprietary early stage programs addressing large markets such as onychomychosis, or nail fungus, and common cold.

SIGA Technologies, Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

AVI Biopharma, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

AVI BioPharma is focused on the discovery and development of RNA–based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI’s antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI’s RNA–based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI’s antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses.

Dynavax Technologies Corporation

admin — Fri, 26 Feb 2010 18:31:21 +0000

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines.

Peregrine Pharmaceuticals Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.

PolyMedix, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

PolyMedix is focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company’s antibiotic compounds are small molecule mimetics of human host-defense proteins and believed to have a completely different mechanism of action from all current antibiotic drugs. A mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broad spectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company’s anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with its goal of developing an antagonist drug that is safer and easier to use than current approved therapy.

Progenics Pharmaceuticals Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, virology and oncology. Progenics is developing RELISTOR(R) (methylnaltrexone bromide) for the treatment of opioid-induced side effects. RELISTOR is currently approved in over 30 countries, including the U.S., E.U. member countries, Canada, Australia and Brazil; marketing applications are pending elsewhere throughout the world.

Optimer Pharmaceuticals, Inc.

admin — Sun, 21 Feb 2010 13:59:35 +0000

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel™ (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers.

Oragenics Inc.

admin — Sun, 21 Feb 2010 13:59:35 +0000

Oragenics, Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The Company also has a number of technologies in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health.

Nabi Biopharmaceuticals

admin — Sun, 21 Feb 2010 13:59:34 +0000

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland.

Nutra Pharma Corporation

admin — Sun, 21 Feb 2010 13:59:34 +0000

Nutra Pharma, through its subsidiary ReceptoPharm, has a pipeline of biopharmaceutical products under development. These research and development pipeline products consist of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis, HIV/AIDS, adrenomyeloneuropathy, herpes, rheumatoid arthritis and pain.

Omni Bio Pharmaceutical, Inc.

admin — Sun, 21 Feb 2010 13:59:34 +0000

Omni Bio Pharmaceutical, Inc. is an emerging biopharmaceutical company formed to acquire, license, and develop existing novel therapies which have substantial commercialization potential. Omni is the licensee of issued and pending patents from the University of Colorado Denver. Omni has been advancing broad-spectrum therapeutics targeting bacterial and viral diseases, biohazards, diabetes and transplant rejection since February 2006. The Company’s core technology is based on novel discoveries made at the University of Colorado involving therapeutic agents already approved for use in humans.

Human Genome Sciences Inc.

admin — Wed, 17 Feb 2010 12:38:22 +0000

The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer.

The Company’s primary focus is rapid progress toward the commercialization of its two lead drugs, BENLYSTA™ (belimumab) for lupus and ZALBIN™ (albinterferon alfa-2b) for hepatitis C. Phase 3 development has been completed successfully for both BENLYSTA and Zalbin. The submission of marketing applications for BENLYSTA is planned in the U.S., Europe and other regions in the first half of 2010. A BLA has been submitted for ZALBIN to the FDA in the United States, and an MAA has been submitted under the brand name JOULFERON® to the EMEA in Europe.

Idenix Pharmaceuticals Inc.

admin — Wed, 17 Feb 2010 12:38:22 +0000

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of infections caused by hepatitis C virus.

Inhibitex Inc.

admin — Wed, 17 Feb 2010 12:38:22 +0000

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. We are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Our pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Hemispherx Biopharma, Inc.

admin — Wed, 17 Feb 2010 09:33:00 +0000

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

BioCryst Pharmaceuticals, Inc

admin — Fri, 12 Feb 2010 23:00:33 +0000

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials: (i) Peramivir, an anti-viral for influenza and (ii) Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL)

Antigenics Inc.

admin — Fri, 12 Feb 2010 22:20:28 +0000

Antigenics is working to develop patient-specific immunotherapeutics and revolutionary treatments for cancers and infectious diseases. The company’s patient-specific cancer vaccine, Oncophage^® (vitespen; formerly HSPPC-96), is currently approved in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence.